Research during the past several decades has made impressive advances in our understanding of the genetic basis of cancer and the aberrant signaling components and mechanisms that drive cancer progression and malignant growth. In recent years, the completion of the sequencing of the human and more recently, of multiple cancer cell genomes, coupled with the rapid development of technologies for the genome-wide genetic, cellular and biochemical profiling of the cancer cell has greatly accelerated these advances. This pace will surely be accelerated exponentially in the future. The accumulation of new information is both impressive and daunting. Therefore, a major challenge of the next decade will be to translate basic cancer research advances into new molecularly targeted cancer therapies. The premise of the Cancer Cell Biology Training Program (CCBTP) is that cancer biology is a unique, interdisciplinary biomedical science that encompasses experimental approaches and didactic knowledge from cell biology, molecular biology, biochemistry, genetics, immunology, microbiology, pharmacology, epidemiology, toxicology, pathology, and physiology. Doctoral students will become well-trained in the paradigms of molecular and cellular biology from more traditional department- or curriculum-based training programs. Rarely will they receive significant training in the pathobiology and treatment of cancer. With an increasing emphasis on multidisciplinary, translational, disease-oriented research, the need to address this deficiency in graduate student training has become of greater urgency. Thus, the broad goal of this program is to provide comprehensive training in translational cancer biology to allow students to effectively contribute to the new wave of translational research. The CCBTP provides a strong emphasis on the histopathology of cancer and exposure to other topics crucial to tumor biology, in particular personalized medicine and molecularly targeted anti-cancer drug discovery and development. Therefore, it fosters the training of doctoral candidates who are uniquely trained and who are clearly distinguished from those of individual departments or other training programs funded by the National Institutes of Health at the University of North Carolina at Chapel Hill

Public Health Relevance

Biomedical research doctoral students are well trained in the paradigms of molecular and cellular biology of cancer, but rarely do these students receive significant training in the pathobiology and treatment of cancer. With an increasing emphasis on translational, disease- oriented research, the need to address this deficiency in graduate student training has become of major urgency. This proposal is for continuation for an interdisciplinary Cancer Cell Biology Training Program for predoctoral students at the University for North Carolina at Chapel Hill.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA071341-18
Application #
8734324
Study Section
Subcommittee B - Comprehensiveness (NCI)
Program Officer
Damico, Mark W
Project Start
1996-09-30
Project End
2017-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
18
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Runge, John S; Raab, Jesse R; Magnuson, Terry (2018) Identification of Two Distinct Classes of the Human INO80 Complex Genome-Wide. G3 (Bethesda) 8:1095-1102
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Vaseva, Angelina V; Blake, Devon R; Gilbert, Thomas S K et al. (2018) KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Cancer Cell 34:807-822.e7
Raab, Jesse R; Runge, John S; Spear, Camarie C et al. (2017) Co-regulation of transcription by BRG1 and BRM, two mutually exclusive SWI/SNF ATPase subunits. Epigenetics Chromatin 10:62
Vitucci, Mark; Irvin, David M; McNeill, Robert S et al. (2017) Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma. Neuro Oncol 19:1237-1247
Irvin, David M; McNeill, Robert S; Bash, Ryan E et al. (2017) Intrinsic Astrocyte Heterogeneity Influences Tumor Growth in Glioma Mouse Models. Brain Pathol 27:36-50
Bailey, Sean T; Smith, Aleisha M; Kardos, Jordan et al. (2017) MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma. Nat Commun 8:15770
McNeill, Robert S; Canoutas, Demitra A; Stuhlmiller, Timothy J et al. (2017) Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma. Neuro Oncol 19:1469-1480
Kechele, Daniel O; Blue, R Eric; Zwarycz, Bailey et al. (2017) Orphan Gpr182 suppresses ERK-mediated intestinal proliferation during regeneration and adenoma formation. J Clin Invest 127:593-607
Hayes, Tikvah K; Neel, Nicole F; Hu, Chaoxin et al. (2016) Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. Cancer Cell 29:75-89

Showing the most recent 10 out of 87 publications